Treatment with benznidazole in association with immunosuppressive drugs in mice chronically infected with Trypanosoma cruzi: investigation into the possible development of neoplasias

Tatamento com benzonidazol em associação com drogas imunossupressoras em camundongos cronicamente infectados com Trypanosoma cruzi: investigação sobre a possibilidade de desenvolvimento de neoplasias

Sonia G. Andrade¹, Igor Marcelo Oliveira Mesquita¹², Jamile F. Jambeiro¹³, Isis F. Magalhães Santos¹ and Renata Siqueira Portella¹

Abstract Benznidazole is recommended in Brazil for the treatment of Trypanosoma cruzi infection in acute and early chronic phases of Chagas’ disease. Observations by others have indicated a higher incidence of neoplasias in immunosuppressed patients, presenting Chagas’ disease reactivation, submitted to treatment with benznidazole. In the present study, we investigated whether there is a potentiation in the generation of lymphomas in chronically infected mice, treated with immunosuppressive drugs and benznidazole. For this, 142 Swiss mice chronically infected with the 21 SF strain of T. cruzi and 72 normal Swiss mice were used. Both infected and normal mice were divided into experimental groups and submitted to one of the following treatment regimens: benznidazole alone; immunosuppressive drugs (azathioprine, betamethasone and cyclosporin); a combination of immunosuppressive drugs and benznidazole; and untreated controls. In the infected group treated with benznidazole, one mouse developed a non-Hodgkin’s lymphoma. This finding has been interpreted as a spontaneous tumor of mice. The study of the chronically infected mice treated with the combination of immunosuppressive drugs and benznidazole demonstrated an absence of lymphomas or other neoplasias. These findings support the indication of benznidazole, as the drug of choice, for immunosuppressed patients that develop a reactivation of Chagas’ disease.


Resumo O benzonidazol é recomendado no Brasil para o tratamento da infecção pelo Trypanosoma cruzi na fase aguda e na fase crônica precoce da doença de Chagas. Observações de outros autores mostraram uma elevação na incidência de neoplasias em pacientes imunossuprimidos, com reativação da doença de Chagas, submetidos a tratamento com o benzonidazol. No presente estudo foi investigado em camundongos cronicamente infectados, tratados com drogas imunossupressoras e com benzonidazol se há uma potencialização de desenvolvimento de linfomas por esta combinação. Para isso foram usados 142 camundongos suíços cronicamente infectados pela cepa 21SF do T.cruzi e 72 camundongos suíços normais. Tanto os camundongos infectados como os normais foram divididos em grupos experimentais submetidos respectivamente a diferentes esquemas de tratamento: com benznidazol apenas; com drogas imunossupressoras (azatioprina, betametasona e ciclosporina); com drogas imunossupressoras mais benznidazol; e controles não tratados. No grupo infectado e tratado com benznidazol, um camundongo desenvolveu um linfoma não-Hodgkin. Este achado foi interpretado como um tumor espontâneo do camundongo. O estudo de camundongos cronicamente infectados e tratados com uma combinação de drogas imunossupressoras e benznidazol demonstrou ausência de linfomas ou de outras neoplasias. Estes achados reforçam a indicação do tratamento com benznidazol como droga de escolha em pacientes imunossuprimidos que desenvolvem reativação da doença de Chagas.

Although the transmission of Chagas’ disease in endemic areas has been successfully controlled\(^2\), patients with chronic infection, and new acute cases, due to different mechanisms of infection, necessitate chemotherapy treatment. As recently reviewed by Coura and Castro\(^1\), nitroimidazolyl benzimidazole continues to be the drug in clinical use in Brazil, with an effective cure in early cases\(^3\) and is recommended by the Fundação Nacional de Saúde\(^4\). Reactivation of Chagas’ disease in immunosuppressed individuals, either due to AIDS\(^5\) \(^6\) \(^7\) \(^8\) \(^9\) \(^{10}\) or to the use of immunosuppressive drugs in transplant patients\(^5\) \(^6\) \(^7\) \(^8\) \(^9\) \(^{10}\) \(^{11}\), has been reported. In such cases, chemotherapeutic treatment is mandatory and benzimidazole is the drug generally used. However, clinical observations have shown an influence of treatment with benzimidazole associated to immunosuppression upon the development of neoplasias, as described by Bocchi et al.\(^8\). The latter treated patients with reactivation of T. cruzi infection, after cardiac transplantation and the use of immunosuppressive drugs. This fact has been confirmed by Almeida\(^8\) and Almeida et al.\(^8\). These observations have implications, mainly related to the replacement of benzimidazole by allopurinol\(^1\), the efficacy of which has not been established. Other authors\(^1\)\(^8\), on the contrary, succeeded in treating the reactivation of Chagas’ disease using benzimidazole, without reference to the development of neoplasias. In four heart-transplant patients, Stolf et al.\(^{12}\), detected 3 cases with reactivation of Chagas’ disease. The treatment of these patients with benzimidazole was successful and a follow-up of 160 to 500 days showed reversion of the acute manifestations, apparently with no detectable clinical or histological sequelae.

Since experimental observations by Teixeira et al.\(^{13}\)\(^ {14}\) regarding the presence of lymphomas in rabbits under treatment with nitroarenes\(^14\), and, specifically, benzimidazole\(^23\) a controversy has been established. Clinical observations by Cançado\(^8\), and a recent review by Coura and Castro\(^1\), did not indicate an increased incidence of neoplasias in chagasic patients treated with benzimidazole. Experimentally, treatment of the chronic phase of infection in mice with benzimidazole, has never resulted in the development of neoplasias, either of the lymphoid organs or others, at least in our experience\(^7\).

With the objective of contributing to the clarification of whether there is in fact a potentiation of mutagenesis and lymphoma generation by the combined use of immunosuppressive drugs and benzimidazole, an investigation was conducted with the experimental murine model of chronic T. cruzi infection using azathioprine, betamethasone and cyclosporin, in doses that could be compared with those used in transplant patients\(^6\).

**MATERIAL AND METHODS**

**Experimental animals.** A group of 178 Swiss mice, weighing 10 to 12g were experimentally infected with the 21 SF strain of T. cruzi classified as biodeme Type II. Inoculation consisted of 4x10\(^3\) trypomastigotes obtained from infected mouse blood. From this infected group, 142 mice that survived up to 100 days of infection, were divided into 4 groups of chronically infected mice as detailed below. For treatment control, 80 normal Swiss mice weighing 10 to 12g were maintained until 100 days. Seventy two surviving mice were divided into 4 groups of uninfected controls. All the experimental mice were sacrificed at the end of treatment.

**Parasitemia and cumulative mortality:** were registered in the acute phase.


**Schedules of immunosuppressive treatment.** The surviving mice were in part, treated with the immunosuppressive drugs: azathioprine (Imuran), betamethasone (celestone) and cyclosporin (Sandimun), 100 days after infection. Doses and administration of the drugs were as follows: azathioprine, 10mg/kg b.w. administered by gavage, 3 days a week for 4 weeks followed by one weekly dose for 90 days.

Betamethasone, 2mg/kg b.w. administered intraperitoneally, 3 days a week, during 4 weeks and once a week during 90 days.

Cyclosporin, 30mg/kg b.w., 3 days a week, by gavage, during 4 weeks, followed by a dose of 15mg/ kg b.w. once a week for 90 days.

**Chemotherapy treatment with benzimidazole.** Treatment with benzimidazole (Rochagan) was initiated 4 weeks after beginning the immunosuppressive treatment. The drug was administered by gavage at a dose of 100mg/kg b.w. day, for 5 days a week, during 90 days, concomitantly with the immunosuppressive treatment.

Group 1 (Inf Co) received sterile saline by gavage (1ml/day) during the same period of treatment.

Parasitaemia was checked before and after treatment. Cumulative mortality was evaluated at the pre-treatment phase until 100 days and during the treatment period for all groups, until 280 days. Mice from the various groups were evaluated according to the total number of leukocytes and the number of lymphocytes in peripheral blood, up to the end of the experiment.

**White blood cell counts:** blood collection was performed during the sacrifice of the mice, by sectioning
the axillary plexus and collecting the blood with heparin into plastic vials, six weeks after the beginning of treatment (for treated animals) and at the same period for untreated controls. White blood cell counts were performed with an automatic Coulter count (T-890).

Statistical analysis: variance test was applied by using the Kruskal-Wallis method for comparing the number of leukocytes and lymphocytes in peripheral blood in normal controls and chronically infected mice from the experimental groups. Comparison was also performed for leukocytes and lymphocytes in chronically infected mice after immunosuppressive and or chemotherapy treatment. For evaluation of the significance of spleen indices in the several groups, the same test (variance test of Kruskal Wallis) was performed. Significance was post-tested by the Dunn’s multiple comparison test.

Serology: serum antibodies were examined by indirect immunofluorescence (IIFT) using culture forms of \textit{T. cruzi} as antigens and rabbit-anti-\textit{T. cruzi} monospecific serum as primary antibody in dilutions of 1:10 until 1:640. As secondary antibody, a goat anti-rabbit IgG conjugated to fluorescein (Sigma) was used.

Histopathological study. Mice from the experimental groups, were sacrificed under anesthesia with ether, 30 days after the end of treatment. The blood was collected for white cell count and serological tests. Body weight and spleen weight were registered for each animal, and the relationship between spleen weight and body weight (spleen index) was determined. The various organs were fixed in Milloning formalin and paraffin embedded. Five micrometer thick (5m) sections of the heart, skeletal muscle, liver, spleen and lymph nodes were stained with Hematoxylin and Eosin.

RESULTS

Parasitemia. Figure 1 shows the characteristic profile of the parasitemic curve of mice in the acute phase of infection with \textit{T. cruzi} strain, biodeme Type II, with the highest peak at the 15th day, and negativation in the chronic phase.

Serology: the mortality rate was 15.2% in the pretreatment period, until 100 days post inoculation (Figure 2). After 100 days of infection, the indices of cumulative mortality varied according to the experimental groups, as shown in Figure 3. The
highest indices of mortality occurred in the groups of mice, both infected and uninfected controls that were treated with immunosuppressive drugs (Groups Inf IM, Inf IM Benz, Co IM), excluding Group Co IM Benz, with no mortality. Also the control group, treated with Benznidazole (Co Benz) presented zero mortality.

**Histopathological study. General data:** The heart of mice chronically infected with *T. cruzi* from Group 2 (Inf Benz) showed regression of the myocarditis, as compared with the infected controls (Inf Co), showing residual, focal inflammatory infiltrates limited to the atria, and focal areas of fibrosis of the myocardium. The other groups of infected mice: Inf Co, Inf IM, Inf IM Benz, presented either mild (+) or moderate (++) focal mononuclear infiltrates in the myocardium and skeletal muscle, with slight variation of intensity.

In several mice from the groups infected and treated with immunosuppressive drugs, pneumonia, pyelonephritis and pericarditis were present, as well as amyloid deposits in the spleen and liver.

**Lymphoid tissue:** In Group 2 (Inf Benz), out of 31 mice chronically infected and treated with benznidazole, one mouse presented neoplastic proliferation of lymphoid cells of the spleen, histologically characterized as a malignant non-Hodgkin's lymphoma (Figure 4-A, B, C and D). Infiltration with blastic lymphoid cells was present in the subepicardium and pericardiac lymph nodes, in the pulmonary tissue and in the sinusoidal and perivascular spaces of the liver (Figure 4-D). In this same group, the other animals showed either normal lymphoid organs or a mild (+) to moderate (++) hyperplasia of the lymphoid follicles of the spleen.

In the other infected groups, the spleen and lymph nodes revealed a normal structure in most of the cases, with mild (+) or moderate (++) hyperplasia of lymphoid follicles.

**Uninfected mice:** In the animals of Group 5 (Co IM) the heart showed mild mononuclear infiltration and small focal areas of myocytolysis of heart. The spleen showed normal structure or atrophy of the lymphoid follicles in 50% of the cases and mild hyperplasia of the lymphoid follicles in the remaining 50%. In the latter cases, amyloid deposits were present in the red pulp as well as in the liver. In the mice of Groups Co Benz, Co IM Benz and NoCo, no significant alterations were observed in the various organs.

**Relationship between spleen weight and body weight (spleen index):** Figure 5 shows the splenic indices for the several experimental groups. Case #15 was not included (Group 2-Inf Benz), that developed a lymphoma and showed a significant increase in spleen weight (2.69g) in comparison with the mean weight of the spleen of the animals of the same group (0.39). Excluding this case, no significant statistical difference was detected between the spleen indices of the four infected groups and the intact controls. However a significant difference was observed between the spleen index of Group 1 (Inf Co) as compared with Group 7 (Co IM Benz) in which a significant decrease of spleen weight was detected (p <0.05).

**White blood cells count.** Results of the evaluation of the total number of leukocytes on infected and uninfected mice, treated or untreated, are shown in Figure 6. No significant statistical differences were detected between the infected groups in comparison with the intact controls. The mouse with a lymphoma (Group 2-Inf Benz) presented a higher number of
Figure 4 - Histopathological aspects: non-Hodgkin’s lymphoma of the spleen: A – sections of the spleen showing neoplastic proliferation of small lymphoid cells, with irregular nuclei, with substitution of the follicular structure of the organ, H & E (400X); B – sections of a lymph node with substitution of the follicular structure by blastic lymphoid cell proliferation, H & E (250X); C – Heart section, with the presence of lymphoid blastic cells in the subepicardium, H & E (100X); D – Invasion of the liver tissue by the neoplastic lymphoid cells, H & E (200X).

Figure 5 - Splenic indices of mice of the experimental groups infected with Trypanosoma cruzi and uninfected controls: 1- Inf Co; 2- Inf Benz; 3 - In IM; 4- Inf IM Benz; 5 - Co IM; 6 - Co Benz; 7 - Co IM Benz; 8 – No Co. Highest spleen index was observed in Group 1 – In Co. No significant difference was detected by statistical analysis between the four infected groups and the normal controls (Group 8 – No Co). A significant difference was observed between the spleen index of Group 1 (Inf Co) compared with Group 7 (Co IM Benz) in which a significant decrease of spleen weight was detected (p <0.05).

Figure 6 - Results of the evaluation of the total number of leukocytes in the peripheral blood of mice representative of the several experimental groups: 1-Inf Co; 2-Inf Benz; 3- In IM; 4-Inf IM Benz; 5 - Co IM; 6 - Co Benz; 7 - Co IM Benz; 8 – No Co. No significant statistical differences were detected between the infected groups and the intact controls. One mouse (*) of Group 2 – Inf Benz that presented a lymphoma of the spleen presented a higher number of leukocytes. Significant decrease of the total number of leukocytes (p <0.05) was observed in Group 7 (Co IM Benz) as compared with Groups 3 (Inf IM) and 4 (Inf IM Benz).
lymphocytes (47.7 x 10^3) in comparison with the other mice of the same group. A significant decrease in the total number of leukocytes was seen in Group 7 (Co IM Benz) as compared with Groups 3 (Inf IM) and 4 (Inf IM Benz). The number of lymphocytes, showed slight variations between the several groups, excluded the mice with lymphoma (Case #15). A statistically significant difference (P <0.05) (Figure 7), was detected between Group 4 (Inf IM Benz) and Group 7 (Co IM Benz).

Serological test (IIFT): Table 1 shows the variation of titers of the IIFT in the several groups. A decrease in the titers occurred in Group 2 (Inf Benz) and varied from 1/40 to 1/640; the other infected groups maintained the serological titers. All uninfected control mice were negative.

<table>
<thead>
<tr>
<th>Infected Groups</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>1:320</td>
<td>1:1280</td>
</tr>
<tr>
<td>Group 2</td>
<td>1:40</td>
<td>1:640</td>
</tr>
<tr>
<td>Group 3</td>
<td>1:320</td>
<td>1:640</td>
</tr>
<tr>
<td>Group 4</td>
<td>1:40</td>
<td>1:320</td>
</tr>
</tbody>
</table>

*Uninfected controls: negative results in the 4 groups

Groups: 1 - Inf Co; 2 - Inf Benz; 3 - Inf IM; 4 - Inf IM Benz

Figure 7 - Evaluation of the number of lymphocytes in the experimental groups: 1 - Inf Co; 2 - Inf Benz; 3 - Inf IM; 4 - Inf IM Benz; 5 - Co IM; 6 - Co Benz; 7 - Co IM Benz; 8 - No Co. The number of lymphocytes showed slight variations between the groups. One mouse (*) of group 2 (Inf Benz) with lymphoma, presented a higher number of lymphocytes. A statistically significant difference (P <0.05) was detected between Group 4 (Inf IM Benz) and Group 7 (Co IM Benz).

DISCUSSION

The results indicate that the association of benznidazole with immunosuppressive drugs did not contribute to the appearance of lymphomas or other neoplasias in mice chronically infected with T. cruzi. In a previous study done with Swiss mice chronically infected with different strains of T. cruzi and submitted to immunosuppressive treatment, but not treated with benznidazole, none developed neoplastic proliferation of lymphoid tissues. In the control group of normal mice, the immunosuppressive treatment combined with benznidazole caused a significant decrease in the number of leukocytes and lymphocytes in peripheral blood and of the spleen index that indicate a response of the lymphoid organs to this type of treatment. However, the infected mice submitted to the same regimens, did not show this type of response. This appears to indicate that the infected mice maintained their leukocyte response, even under the influence of immunosuppressive drugs or benznidazole treatment, with mild to moderate hyperplasia of lymphoid follicles, without proliferation of the cells of the germinal centers.

In the present study a non-Hodgkin's lymphoma of the spleen and lymph nodes was detected in one mouse of the group treated exclusively with benznidazole. The finding of one case of non-Hodgkin's lymphoma out of 31 chronically infected mice treated with chemotherapy (3.2%), could not be considered a priori as evidence of a direct action of the nitroimidazolyl on its development. Spontaneous lymphoma in mice has been registered not only in
some inbred strains most susceptible to the development of such tumors as in outbred strains of mice currently used in laboratories, as reported by Furmanski and Rich. According to these authors, leukemia and other hematological malignancy in mice are estimated to have a spontaneous incidence of 1 to 2%. Many highly inbred strains of mice can be selected with a high incidence of these types of neoplasias, for example the SLJ16. Considering the Swiss mice, Furmanski and Rich, registered the results of different authors with a variation from 1 to 22.8% in the incidence of spontaneous lymphomas.

The present investigation contributed to demonstrating that the combined use of immunosuppressive drugs with benznidazole, in doses that mimic the treatment of transplant patients, did not effectively determine the appearance of lymphomas in Swiss outbred mice strain. These have proven not to be refractory to the spontaneous development of this type of tumor as presently demonstrated. Our findings support the indication of treatment with benznidazole for immunosuppressed patients that develop reactivation of T. cruzi infection.

**REFERENCES**